UW Accepts Enrollment in Tosedostat Phase II

Cell Therapeutics, Inc. introduced the fact that the University of Washington ("UW") has begun enrolling affected individuals in a randomized phase II study trying the mixture of tosedostat with cytarabine or decitabine for elderly affected individuals along with newly-diagnosed acute myeloid leukemia ("AML") or harmful myelodysplastic syndrome ("MDS").

"This is the initial study to see the results of tosedostat in conjunction with cytarabine or decitabine being a first-line session. The research will consider how well affected individuals tolerate each of these combinations, and also their effectiveness”.

“Given that there has also been no major improvements in treatment of aged affected individuals with AML, and the results of a preceding evaluation of tosedostat in isolation in relapsed or refractory affected individuals with AML or MDS showed guaranteeing anti-leukemic consequences and satisfactory tolerability, we are positive that the study will show that tosedostat increases the restricted efficacy of such widely used anti-leukemic agents”.